4.7 Article

Uric acid and allantoin levels in Down syndrome:: antioxidant and oxidative stress mechanisms?

Journal

CLINICA CHIMICA ACTA
Volume 341, Issue 1-2, Pages 139-146

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.cccn.2003.11.020

Keywords

Down syndrome; oxidative stress; purine metabolism; uric acid; allantoin

Ask authors/readers for more resources

Background: Down syndrome (DS) is a chromosomal abnormality (trisomy 21) leading to mental retardation, to the characteristic change of individual's phenotype and to the pathological features of Alzheimer disease. Patients with DS have elevated ratio of superoxide dismutase to (catalase plus glutathione peroxidase) with respect to controls in all age categories suggesting that oxidative imbalance contributes to the clinical manifestation of accelerated aging. Results: We report that persons with DS have elevated uric acid levels compared with controls, 348.56 +/- 22.78 versus 284.00 +/- 20.86 mumol/ 1 (p = 0.018). The levels of hypoxanthine and xanthine in DS children (6.35 +/- 0.31 and 1.02 +/- 0.23 mumol/l) were significantly lower than in controls (7.83 +/- 0.59 and 2.43 +/- 0.66 mumol/l). This result suggests increased conversion of hypoxanthine and xanthine to uric acid with subsequent free radical-dependent oxidation of uric acid to allantoin, mechanisms potentiated by the oxidative stress in DS. Allantoin is a nonenzymatic oxidative product of uric acid in human. In DS individuals, the levels of allantoin were significantly higher than those in healthy controls (18.58 +/- 2.27 and 14.07 +/- 1.07 mumol/l, respectively, p = 0.03). Conclusions: Our data supported the presumption of increased oxidative stress in DS. (C) 2004 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available